Teladoc Health, Inc. $TDOC Shares Acquired by Counterpoint Mutual Funds LLC

Key Points

• Counterpoint Mutual Funds sharply increased its Teladoc position by 1,017.4% in the third quarter, purchasing 1.50 million additional shares. It now owns 1.65 million shares valued at approximately $9.6 million, while institutional investors collectively hold 76.82% of TDOC.
• Teladoc’s stock opened at $5.68, near the lower end of its 52-week range of $4.40 to $9.89. The company reported a quarterly loss of $0.21 per share, better than estimates, but revenue declined 4% year over year to $606.9 million.
• Analyst sentiment remains mixed, with five Buy, ten Hold and one Sell rating, producing a consensus Hold rating and $7.54 price target. CEO Charles III sold shares worth $108,610 to cover tax withholding obligations, while insiders own 0.70% of the company.

Counterpoint Mutual Funds LLC increased its position in shares of Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 1,017.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,650,165 shares of the health services provider's stock after purchasing an additional 1,502,488 shares during the quarter. Teladoc Health makes up approximately 0.8% of Counterpoint Mutual Funds LLC's holdings, making the stock its 26th biggest holding. Counterpoint Mutual Funds LLC owned approximately 0.91% of Teladoc Health worth $9,571,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in TDOC. Vontobel Holding Ltd. grew its stake in Teladoc Health by 98.4% during the third quarter. Vontobel Holding Ltd. now owns 93,210 shares of the health services provider's stock worth $541,000 after buying an additional 46,227 shares during the last quarter. ABS Direct Equity Fund LLC bought a new position in shares of Teladoc Health in the second quarter valued at approximately $1,513,000. WINTON GROUP Ltd raised its stake in shares of Teladoc Health by 402.4% in the second quarter. WINTON GROUP Ltd now owns 227,100 shares of the health services provider's stock valued at $1,926,000 after acquiring an additional 181,900 shares during the last quarter. Nykredit A S acquired a new position in shares of Teladoc Health in the 2nd quarter worth approximately $27,000. Finally, HighTower Advisors LLC boosted its holdings in shares of Teladoc Health by 20.8% in the 2nd quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider's stock worth $143,000 after acquiring an additional 2,893 shares in the last quarter. 76.82% of the stock is owned by institutional investors.

Insider Transactions at Teladoc Health

In related news, CEO Charles III sold 17,805 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the sale, the chief executive officer directly owned 465,535 shares in the company, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company's stock.

Teladoc Health Price Performance

TDOC stock opened at $5.68 on Friday. The company has a 50 day moving average price of $6.22 and a 200 day moving average price of $6.87. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The stock has a market capitalization of $1.03 billion, a PE ratio of -5.74 and a beta of 2.14.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. The firm had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. The business's quarterly revenue was down 4.0% compared to the same quarter last year. During the same period last year, the company earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. As a group, equities analysts expect that Teladoc Health, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on TDOC shares. Bank of America increased their price target on Teladoc Health from $9.00 to $10.50 and gave the stock a "buy" rating in a research report on Tuesday, July 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Canaccord Genuity Group cut their price objective on Teladoc Health from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, Citigroup reduced their price objective on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating on the stock in a research note on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $7.54.

Teladoc Health Profile

Teladoc Health, Inc NYSE: TDOC provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company's offerings include Teladoc's telehealth services, BetterHelp's online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.